Protein kinase D enzymes: novel kinase targets in pancreatic cancer

Expert Rev Gastroenterol Hepatol. 2015;9(9):1143-6. doi: 10.1586/17474124.2015.1069706. Epub 2015 Jul 17.

Abstract

Pancreatic ductal adenocarcinoma (PDA) is characterized by advanced stage desmoplastic tumors with a high prevalence of genetic abnormalities. Occurrence of PDA is linked to activating Kras mutations and aberrant epidermal growth factor receptor signaling, leading to additional activation of wild-type Kras. As Kras is difficult to target, there is a constant need to identify novel targets acting downstream of this molecule in driving the formation or progression of PDA. Recently, it was shown that protein kinase D enzymes not only are increasingly expressed in PDA but also causatively linked to the development and progression of this cancer. They act downstream of both mutant Kras and growth factors and therefore may represent ideal novel targets.

Keywords: acinar-to-ductal metaplasia; isoforms; pancreatic cancer; protein kinase D.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / metabolism*
  • Carcinoma, Pancreatic Ductal / drug therapy
  • Carcinoma, Pancreatic Ductal / enzymology*
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / enzymology*
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism*
  • Proto-Oncogene Proteins p21(ras) / metabolism
  • Signal Transduction

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Enzyme Inhibitors
  • KRAS protein, human
  • protein kinase D
  • Protein Kinase C
  • Proto-Oncogene Proteins p21(ras)